Welcome to MOLOGEN AG

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 


The biopharmaceutical company MOLOGEN AG presented two posters on its lead compound, the TLR9 agonist lefitolimod at the SITC 2018 Congress (The Society for Immunotherapy of Cancer) in Washington D.C., U.S. (07 – 11 November 2018). [more]

Publication of an inside information pursuant to Section 17 of the regulation (EU) No. 596/2014 The Executive Board of MOLOGEN AG (ISIN DE000A2LQ900, SIN A2L Q90) (the "Company") reached today, with the approval of the Supervisory Board, an agreement with the majority creditor of the (i) €2,540,000 6% convertible bond 2016/2024 (ISIN... [more]

Annual Report 2017

Download pdf

Quarterly Statement as at 31 March 2018

Download pdf

Half-Yearly Financial Statement as at 30 June 2018

Download pdf

Quarterly Statement as at 30 September 2018

Download pdf